The stock of Reneo Pharmaceuticals Inc (RPHM) has gone down by -8.39% for the week, with a -10.88% drop in the past month and a -22.94% drop in the past quarter. The volatility ratio for the week is 8.20%, and the volatility levels for the past 30 days are 6.70% for RPHM. The simple moving average for the past 20 days is -12.61% for RPHM’s stock, with a -32.55% simple moving average for the past 200 days.
Is It Worth Investing in Reneo Pharmaceuticals Inc (NASDAQ: RPHM) Right Now?
Company’s 36-month beta value is 0.21.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RPHM is 21.72M, and currently, short sellers hold a 14.86% ratio of that floaft. The average trading volume of RPHM on September 16, 2024 was 121.30K shares.
RPHM) stock’s latest price update
The stock of Reneo Pharmaceuticals Inc (NASDAQ: RPHM) has decreased by -7.09 when compared to last closing price of 1.41.Despite this, the company has seen a loss of -8.39% in its stock price over the last five trading days. businesswire.com reported 2024-09-03 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo shareholders. Pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. Halper Sadeh encourages Reneo shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalpe.
Analysts’ Opinion of RPHM
H.C. Wainwright gave a rating of “Neutral” to RPHM, setting the target price at $1.50 in the report published on December 15th of the previous year.
RPHM Trading at -11.17% from the 50-Day Moving Average
After a stumble in the market that brought RPHM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.78% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 8.20%, as shares sank -16.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.25% lower at present.
During the last 5 trading sessions, RPHM fell by -8.39%, which changed the moving average for the period of 200-days by -77.80% in comparison to the 20-day moving average, which settled at $1.4865. In addition, Reneo Pharmaceuticals Inc saw -18.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RPHM starting from Leonard Braden Michael, who purchase 171,339 shares at the price of $1.39 back on Aug 13 ’24. After this action, Leonard Braden Michael now owns 2,843,533 shares of Reneo Pharmaceuticals Inc, valued at $238,590 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Reneo Pharmaceuticals Inc, purchase 100,487 shares at $1.41 during a trade that took place back on Aug 14 ’24, which means that Leonard Braden Michael is holding 2,944,020 shares at $142,008 based on the most recent closing price.
Stock Fundamentals for RPHM
Current profitability levels for the company are sitting at:
- -85.67 for the present operating margin
- 0.84 for the gross margin
The net margin for Reneo Pharmaceuticals Inc stands at -77.03. The total capital return value is set at -0.81. Equity return is now at value -54.00, with -49.87 for asset returns.
Based on Reneo Pharmaceuticals Inc (RPHM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -80.61. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -61.89.
Currently, EBITDA for the company is -82.55 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 11.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 57.86.
Conclusion
In a nutshell, Reneo Pharmaceuticals Inc (RPHM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
